title: Individualizing care for women with early-stage breast cancer: the role of molecular assays.
abstract: Traditionally, a variety of factors were used to make adjuvant treatment decisions in breast cancer, but none of those factors, except grade, has a consistent association with sensitivity to chemotherapy or endocrine therapy. However, oncologists now are able to use molecular assays as a component of decision making for adjuvant therapy. This article focuses on the use of two of those molecular assays and their implications for nurses.
authors.affiliation: Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA. georgia_litsas@dfci.harvard.edu
authors.forename: Georgia
authors.initials: G
authors.lastname: Litsas
mesh_terms: D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000451:nursing / Q000628:therapy*; D003131:Combined Modality Therapy; D055088:Early Detection of Cancer; D005260:Female; D006801:Humans; D025202:Molecular Diagnostic Techniques; D057285:Precision Medicine